Processa Pharmaceuticals (PCSA) Cash & Equivalents (2012 - 2026)

Processa Pharmaceuticals (PCSA) has 15 years of Cash & Equivalents data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Cash & Equivalents fell 41.32% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 41.32% YoY) and the FY2025 annual result came in at $5.5 million, up 364.77% from the prior year.
• Cash & Equivalents eased to $1.7 million in Q1 2026, from $5.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $14.4 million in Q1 2022 to a low of $1.2 million in Q4 2024.
• A 5-year average of $6.8 million and a median of $6.5 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 74.69% — and 2025, when it jumped 364.77%.
• Tracing PCSA's Cash & Equivalents over 5 years: stood at $6.5 million in 2022, then declined by 27.64% to $4.7 million in 2023, then tumbled by 74.69% to $1.2 million in 2024, then jumped by 364.77% to $5.5 million in 2025, then sank by 69.3% to $1.7 million in 2026.
• The last three Cash & Equivalents figures came in at $1.7 million (Q1 2026), $5.5 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.